Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

BACKGROUND: Early detection of oesophageal cancer improves outcomes; however, the optimal strategy for identifying patients at increased risk from the pre-cancerous lesion Barrett’s oesophagus (BE) is not clear. The Cytosponge, a novel non-endoscopic sponge device, combined with the biomarker Trefoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Offman, Judith, Muldrew, Beth, O’Donovan, Maria, Debiram-Beecham, Irene, Pesola, Francesca, Kaimi, Irene, Smith, Samuel G., Wilson, Ashley, Khan, Zohrah, Lao-Sirieix, Pierre, Aigret, Benoit, Walter, Fiona M., Rubin, Greg, Morris, Steve, Jackson, Christopher, Sasieni, Peter, Fitzgerald, Rebecca C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091067/
https://www.ncbi.nlm.nih.gov/pubmed/30075763
http://dx.doi.org/10.1186/s12885-018-4664-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6091067/
https://www.ncbi.nlm.nih.gov/pubmed/30075763
http://dx.doi.org/10.1186/s12885-018-4664-3

Ejemplares similares